ITIgor Tsaur

Igor Tsaur

*This is an algorithmically generated author record based on publicly available information.

Igor Tsaur has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PD23-12 UTILIZATION OF FACEBOOK, TWITTER, YOUTUBE AND INSTAGRAM IN THE PROSTATE CANCER COMMUNITY

    by Julian Struck, Fabian Siegel, Mario Kramer, Igor Tsaur, Axel Heidenreich, Axel Haferkamp, Axel Merseburger, Hendrik Borgmann, Johannes Salem

    To measure the usage rate of social media (SoMe) resources in the prostate cancer community, we performed a comprehensive quantitative and qualitative assessment of SoMe activity on the topic of PCa on the four most frequented platforms.

  • PD34-10 ATTRACTIVENESS AND ACCESSIBILITY OF FOCAL THERAPY FOR PROSTATE CANCER: RESULTS OF AN INTERNATIONAL WEB-BASED SURVEY

    by Giancarlo Marra, Guillaume Ploussard, Piet Ost, Pieter J.L. De Visschere, Prasanna Sooriakumaran, Alberto Briganti, Giorgio Gandaglia, Derya Tilki, Christian I. Surcel, Igor Tsaur, et al.

    Focal therapy (FT) of localized prostate cancer (PCa) yields promising medium-term oncological and functional outcomes. FT role in multi-focal disease and in low-risk cancer suitable for active surveillance (AS), its recurrence rates and lack of long-term data remain open issues. Guidelines limit its use to clinical trials and FT is available only in a few academic centres. The urologists′ opinion over FT has never been investigated. We assessed the current opinion and accessibility of FT in the European urological community.

  • Ruptured angiomyolipoma of the kidney: a rare differential diagnosis of flank pain

    by Maximilian Peter Brandt, Igor Tsaur, Stefan Vallo, Marieke Krimphove, Claudia Frellesen, Thomas Vogl, Thomas Hoefner, Georg Bartsch, Axel Haferkamp, Christian Thomas

    (2017). Ruptured angiomyolipoma of the kidney: a rare differential diagnosis of flank pain. Scandinavian Journal of Urology: Vol. 51, No. 4, pp. 342-344.


  • Amygdalin delays cell cycle progression and blocks growth of prostate cancer cells in vitro

    by Jasmina Makarević, Igor Tsaur, Eva Juengel, Hendrik Borgmann, Karen Nelson, Christian Thomas, Georg Bartsch, Axel Haferkamp, Roman A. Blaheta


  • Open Access

    Utilization of surgical safety checklists by urological surgeons in Germany: a nationwide prospective survey

    by Hendrik Borgmann, Sarah Helbig, Michael A. Reiter, Tanja Hüsch, David Schilling, Igor Tsaur, Axel Haferkamp

    We aimed to investigate the contemporary usage rate and habits of the WHO Surgical Safety Checklist (SSC) in German urological departments. We designed a 26-item questionnaire that was sent to all urological departments in Germany. The primary aim of this study was to evaluate the usage rate of the SSC. Secondary aims were to compare perioperative characteristics of users vs. non-users of the SSC and to assess circumstances of the SSC application. A total of 213 of 234 (91 %) urological departments were users of the SSC, and 21 (9 %) were non-users. SSC users had more often a standard protocol, took less time and had fewer people involved for checking perioperative patient data compared to non-users. Financial budgeting for the SSC existed in 55 (24 %) departments and for patient safety in 73 (32 %) departments. The usage rate of the SSC in urological departments in Germany is high despite restricted financial budgeting. Users of the SSC profit by saving time and manpower for checking perioperative patient data.


  • Open Access

    Feasibility, complications and oncologic results of a limited inguinal lymph node dissection in the management of penile cancer

    by Igor Tsaur, Carmen Biegel, Kilian Gust, Tanja Huesch, Hendrik Borgmann, Maximilian P.J.K. Brandt, Martin Kurosch, Michael Reiter, Georg Bartsch, David Schilling, et al.

    Key words: Penile Neoplasms; Neoplasm Metastasis; Lymph Node Excision; Morbidity; Recurrence


  • Open Access

    sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients

    by Igor Tsaur, Kristina Thurn, Eva Juengel, Kilian M. Gust, Hendrik Borgmann, Rene Mager, Georg Bartsch, Elsie Oppermann, Hanns Ackermann, Karen Nelson, et al.

    Measurement of prostate-specific antigen (PSA) advanced the diagnostic and prognostic potential for prostate cancer (PCa). However, due to PSA’s lack of specificity, novel biomarkers are needed to improve risk assessment and ensure optimal personalized therapy. A set of protein molecules as potential biomarkers was therefore evaluated in serum of PCa patients. Serum samples from patients undergoing radical prostatectomy (RPE) for biopsy-proven PCa without neoadjuvant treatment were compared to serum samples from healthy subjects. Preliminary screening of 119 proteins in 10 PCa patients and 10 controls was carried out by the Proteome Profiler Antibody Array. Those markers showing distinct differences between patients and controls were then further evaluated by ELISA in the serum of 165 PCa patients and 19 controls. Uni- and multivariate as well as correlation analysis were performed to test the capability of these molecules to detect disease and predict pathological outcome. Screening showed that soluble (s)E-cadherin, E-selectin, MMP2, MMP9, TIMP1, TIMP2, Galectin and Clusterin warranted further evaluation. sE-Cadherin, TIMP1, Galectin and Clusterin were significantly over- and MMP9 under-expressed in PCa compared to controls. The concentration of sE-cadherin, MMP2 and Clusterin correlated negatively and that of MMP9 and TIMP1 positively with the Gleason Sum at prostatectomy. Only sE-cadherin significantly correlated with the highest Gleason pattern. Compared to serum PSA, sE-cadherin provided an independent and better matching predictive ability for discriminating PCas with an upgrade at RPE and aggressive tumors with a Gleason Sum ≥7. sE-cadherin performed most favorably from a large panel of serum proteins in terms of diagnostic and predictive potential in curatively treatable PCa. sE-cadherin merits further investigation as a biomarker for PCa.


  • MP8-11 QUALITY, ACCESSIBILITY AND READABILITY OF ONLINE HEALTH INFORMATION ON URINARY INCONTINENCE

    by Hendrik Borgmann, Jan-Henning Wölm, Michael Reiter, Kilian Gust, Stefan Vallo, Georg Bartsch, Roman Blaheta, Igor Tsaur, Axel Haferkamp

  • Open Access

    Intensified antineoplastic effect by combining an HDAC‐inhibitor, an mTOR‐inhibitor and low dosed interferon alpha in prostate cancer cells

    by Igor Tsaur, Lukasz Hudak, Jasmina Makarević, Eva Juengel, Jens Mani, Hendrik Borgmann, Kilian M. Gust, David Schilling, Georg Bartsch, Karen Nelson, et al.

    A significant proportion of men diagnosed with prostate cancer (PCa) eventually develop metastatic disease, which progresses to castration resistance, despite initial response to androgen deprivation. As anticancer therapy has become increasingly effective, acquired drug resistance has emerged, limiting efficacy. Combination treatment, utilizing different drug classes, exemplifies a possible strategy to foil resistance development. The effects of the triple application of the histone deacetylase (HDAC) inhibitor valproic acid (VPA), the mammalian target of rapamycin inhibitor everolimus and low dosed interferon alpha (IFNα) on PCa cell growth and dissemination capacity were investigated. For that purpose, the human PCa cell lines, PC‐3, DU‐145 and LNCaP were treated with the combined regimen or separate single agents. Cell growth was investigated by the MTT dye reduction assay. Flow cytometry served to analyse cell cycle progression. Adhesion to vascular endothelium or immobilized collagen, fibronectin and laminin was quantified. Migration and invasion characteristics were determined by the modified Boyden chamber assay. Integrin α and β subtypes were investigated by flow cytometry, western blotting and RT‐PCR. Integrin related signalling, Epidermal Growth Factor Receptor (EGFr), Akt, p70S6kinase and extracellular signal‐regulated kinases (ERK)1/2 activation were also assessed. The triple application of VPA, everolimus and low dosed IFNα blocked tumour cell growth and dissemination significantly better than any agent alone. Antitumour effects were associated with pronounced alteration in the cell cycle machinery, intracellular signalling and integrin expression profile. Combining VPA, everolimus and low dosed IFNα might be a promising option to counteract resistance development and improve outcome in PCa patients.


  • Open Access

    CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study

    by Igor Tsaur, Anika Noack, Jasmina Makarevic, Elsie Oppermann, Ana Maria Waaga-Gasser, Martin Gasser, Hendrik Borgmann, Tanja Huesch, Kilian M. Gust, Michael Reiter, et al.

    Prostate specific antigen is not reliable in diagnosing prostate cancer (PCa), making the identification of novel, precise diagnostic biomarkers important. Since chemokines are associated with more aggressive disease and poor prognosis in diverse malignancies, we aimed to investigate the diagnostic relevance of chemokines in PCa. Preoperative and early postoperative serum samples were obtained from 39 consecutive PCa patients undergoing radical prostatectomy. Serum from 15 healthy volunteers served as controls. Concentrations of CXCL12, CXCL13, CX3CL1, CCL2, CCL5, and CCL20 were measured in serum by Luminex. The expression activity of CXCR3, CXCR4, CXCR5, CXCR7, CXCL12, CXCL13, CX3CR1, CXCL1, CCR2, CCR5, CCR6, CCR7, CCL2, and CCL5 mRNA was assessed in tumor and adjacent normal tissue of prostatectomy specimens by quantitative real-time polymerase chain reaction. The associations of these chemokines with clinical and histological parameters were tested. The gene expression activity of CCL2 and CCR6 was significantly higher in tumor tissue compared to adjacent normal tissue. CCL2 was also significantly higher in the blood samples of PCa patients, compared to controls. CCL5, CCL20, and CX3CL1 were lower in patient serum, compared to controls. CCR2 tissue mRNA was negatively correlated with the Gleason score and grading. Chemokines are significantly modified during tumorigenesis of PCa, and CCL2 is a promising diagnostic biomarker.